toxic
test
lowph
buffer
hela
cell
monolay
cell
monolay
hela
cell
andor
hbec
incub
min
ml
test
buffer
along
ml
medium
next
cell
wash
pb
ph
medium
replac
treatment
repeat
twice
interv
twentyfour
hour
first
treatment
unstain
cell
examin
light
microscop
cytopath
effect
next
cell
fix
mlwell
buffer
formalin
h
stain
crystal
violet
ethanol
integr
cell
monolay
evalu
scale
depend
intens
stain
surviv
cell
intact
cell
monolay
vitro
viru
inactiv
test
incub
ml
either
moll
citratephosph
cp
buffer
ph
moll
ascorb
ph
moll
phthalat
ph
pb
ph
neg
control
second
seri
experi
rang
respiratori
virus
includ
rsv
influenza
sever
hrv
serotyp
test
experi
viral
suspens
dilut
close
simul
condit
might
occur
nasopharynx
topic
applic
nasal
spray
viral
titer
determin
min
incub
effect
intermitt
exposur
lowph
buffer
viral
growth
vitro
hela
cell
monolay
inocul
h
treat
lowph
buffer
pb
min
procedur
repeat
h
infect
viral
titer
determin
h
addit
uninfect
cell
monolay
also
briefli
expos
min
lowph
buffer
moll
cp
ph
moll
phthalat
ph
pb
ph
time
period
neither
citrat
cp
treatment
produc
cell
toxic
phthalat
treatment
produc
extens
thin
detach
cell
monolay
data
shown
three
studi
conduct
test
toler
effect
repeat
administr
lowph
buffer
test
antivir
effect
vivo
protocol
review
approv
human
subject
committe
test
institut
univers
wisconsin
hospit
hull
east
ride
local
research
ethic
committe
toler
lowph
nasal
spray
healthi
volunt
determin
whether
lowph
nasal
spray
would
toler
use
repeatedli
doubleblind
placebocontrol
random
crossov
studi
conduct
inform
consent
obtain
normal
healthi
volunt
age
year
spray
either
mol
l
cp
ph
moll
cp
ph
normal
salin
ph
nostril
time
daili
day
spray
also
contain
standard
preserv
thicken
agent
subject
use
nasal
spray
consecut
rest
period
spray
spray
administ
shot
nostril
time
daili
follow
rest
period
nasal
spray
use
physic
examin
nasal
mucosa
perform
baselin
end
treatment
period
addit
diari
kept
record
symptom
congest
headach
etc
scale
none
mild
moder
sever
day
washout
period
administr
nasal
spray
nasal
spray
effect
intranas
ph
twelv
healthi
adult
volunt
age
year
without
current
nasal
symptom
recruit
studi
none
use
topic
nasal
spray
preced
month
three
differ
volum
ph
citric
acidlpyroglutam
acidphyt
acid
solut
administ
via
nasal
spray
pump
valoi
nostril
achiev
dose
pump
spray
twice
mucos
epitheli
surfac
ph
measur
obtain
multius
pediatr
extern
refer
ph
cathet
medtron
insert
via
vestibul
point
nose
inferior
turbin
septum
nasopharynx
measur
obtain
baselin
min
dose
order
dose
test
randomli
alloc
investig
effect
lowph
nasal
spray
experiment
hrv
infect
determin
whether
intranas
administr
lowph
buffer
would
either
prevent
lessen
sever
clinic
cold
pilot
prospect
random
placebocontrol
studi
conduct
use
experiment
inocul
provid
inform
consent
healthi
volunt
age
year
detect
neutral
antibodi
randomli
assign
receiv
either
activ
treatment
placebo
treatment
solut
consist
citrat
ph
phytic
acid
chelat
agent
lpyroglutam
acid
phenyl
ethyl
alcohol
preserv
carbopol
thicken
eucalyptol
placebo
solut
consist
normal
salin
ph
along
thicken
preserv
begin
min
inocul
test
solut
either
lowph
buffer
placebo
selfadminist
time
day
pm
pm
pm
day
volum
spray
nostril
administr
second
third
fourth
dose
test
product
day
subject
record
presenc
sever
symptom
time
symptom
diari
cold
symptom
sneez
rhinorrhea
nasal
obstruct
sore
throat
cough
headach
malais
tired
rundown
feel
chilli
rate
use
scale
absenc
mild
moder
sever
score
type
symptom
day
adjust
baselin
subtract
correspond
score
day
averag
daili
score
calcul
nasal
wash
perform
symptom
assess
first
morn
dose
day
subject
consid
cold
met
follow
modifi
jackson
criteria
confirm
infect
evidenc
presenc
nasal
wash
least
increas
titer
serum
neutral
antibodi
total
symptom
score
either
presenc
rhinorrhea
day
subject
impress
cold
cold
durat
defin
number
day
subject
daili
symptom
score
greater
threshold
valu
asymptomat
infect
cold
durat
assign
durat
reduc
ph
induc
administr
differ
volum
nasal
spray
compar
calcul
area
curv
auc
exploratori
natur
studi
adjust
made
control
experimentwis
type
error
rate
comparison
lowph
nasal
formul
placebo
control
made
use
fisher
exact
test
percentag
inocul
subject
becam
infect
percentag
inocul
subject
becam
infect
show
presenc
cold
wilcoxon
rank
sum
test
total
daili
individu
symptom
score
subject
becam
infect
number
day
cold
subject
becam
infect
number
day
shed
inocul
subject
amount
shed
day
inocul
subject
comparison
p
valu
shown
unless
otherwis
indic
type
error
rate
use
statist
hypothesi
test
suscept
hrv
rsv
piv
influenza
viru
low
ph
sever
lowph
buffer
select
studi
buffer
capac
rang
ph
report
inactiv
hrv
select
buffer
maintain
ph
dilut
least
pb
ph
addit
goal
experi
develop
solut
use
topic
nose
sever
buffer
chosen
poor
solubl
mucos
irrit
strong
tast
phthalat
cp
ascorb
buffer
caus
mark
loss
infecti
viru
titer
effect
pronounc
figur
incub
min
viru
suspens
equal
volum
moll
cp
ph
lost
titer
lost
appreci
titer
even
incub
min
acid
buffer
influenza
show
reduct
infect
min
averag
reduct
min
low
ph
diminish
titer
either
rsv
effect
intermitt
exposur
lowph
buffer
viral
growth
vitro
natur
hrv
infect
initi
small
inoculum
viru
must
spread
extracellularli
infect
addit
cell
experi
conduct
model
process
vitro
determin
whether
lowph
nasal
spray
could
interrupt
extracellular
spread
hrv
exposur
hela
cell
low
ph
citrat
cp
buffer
interv
reduc
yield
viru
figur
contrast
wash
cell
pb
ph
produc
modest
reduct
viral
titer
compar
untreat
cell
vs
figur
toler
lowph
nasal
spray
normal
volunt
spray
gener
well
toler
subject
complet
phase
studi
differ
note
total
symptom
score
tabl
individu
sign
symptom
analyz
separ
sore
throat
report
often
individu
treat
either
moll
cp
compar
salin
also
reflect
higher
mean
score
symptom
tabl
nasal
erythema
physic
examin
report
often
individu
treat
salin
grouprel
differ
sign
symptom
buffer
nasal
spray
lower
ph
vivo
total
healthi
volunt
complet
intranas
ph
studi
intranas
administr
ph
citric
acidlpyroglutam
acidphyt
acid
solut
caus
transient
ph
chang
region
nose
effect
dose
time
depend
figur
tabl
greatest
effect
ph
unit
reduct
seen
min
administr
ph
remain
significantli
lower
baselin
ph
min
dose
produc
significantli
greater
ph
reduct
compar
dose
auc
p
respect
nasopharynx
similar
trend
note
area
nose
data
shown
effect
lowph
nasal
spray
outcom
experiment
induc
infect
total
subject
complet
studi
tabl
subject
infect
indic
shed
viru
nasal
secret
andor
increas
antibodi
titer
among
infect
subject
activ
nasal
formul
group
placebo
group
subject
complet
data
set
analys
base
previou
symptom
assess
placebo
group
subject
inocul
experienc
cold
symptom
activ
treatment
group
lower
cold
incid
rate
differ
reflect
differ
subject
treatment
group
reach
statist
signific
activ
treatment
lower
total
symptom
score
median
daili
symptom
score
figur
compar
placebo
similarli
administr
lowph
nasal
spray
reduc
individu
symptom
score
shorten
durat
ill
data
shown
almost
subject
becam
infect
challeng
viru
treatment
group
placebo
group
amount
viru
nasal
lavag
sampl
day
quantifi
median
viru
level
lower
treatment
group
compar
placebo
group
vs
p
modest
correl
viral
shed
symptom
score
group
whole
rs
p
modifi
treatment
statu
seriou
advers
event
ae
report
one
earli
withdraw
relat
abdomin
discomfort
number
subject
report
ae
treatment
group
regardless
causal
subject
activ
nasal
formul
group
subject
placebo
group
among
ae
judg
possibl
probabl
relat
treatment
subject
activ
nasal
formul
group
report
fever
subject
placebo
group
report
abdomin
discomfort
subject
report
applic
site
reaction
activ
spray
report
singl
day
resolv
day
conduct
seri
vitro
vivo
experi
determin
whether
sensit
hrv
low
ph
might
use
develop
new
treatment
approach
respiratori
viral
infect
survey
common
respiratori
virus
show
acid
condit
inhibit
replic
hrv
serotyp
lesser
extent
influenza
viru
mani
low
ph
buffer
test
harm
cell
monolay
vitro
differ
solut
evalu
tissu
cultur
citrat
chosen
studi
nontox
readili
kill
viru
reduct
buffer
capac
remain
low
ph
even
dilut
vitro
model
intermitt
exposur
nasal
spray
suggest
interrupt
extracellular
spread
viru
lowph
buffer
may
abl
either
prevent
reduc
sever
clinic
cold
lowph
buffer
lower
nasal
ph
least
min
produc
minor
irrit
nose
healthi
volunt
smallscal
pilot
clinic
trial
perform
use
experiment
inoculationwith
experiment
inocul
hrv
provid
attract
model
test
antivir
compound
allow
inocul
standard
viru
detail
kinet
observ
evolut
resolut
cold
combin
low
ph
chelat
agent
reduc
amount
viral
shed
acut
cold
reduc
common
cold
symptom
although
clinic
benefit
demonstr
present
studi
confirm
feasibl
use
inexpens
low
ph
solut
inhibit
viral
replic
major
question
rais
result
treatment
abl
reduc
viral
shed
clinic
symptom
one
factor
statist
power
studi
possibl
despit
antivir
effect
solut
caus
sensat
nose
confus
cold
symptom
although
ae
profil
citrat
nose
normal
volunt
similar
normal
salin
possibl
effect
could
accentu
presenc
viral
infect
altern
explan
lack
clinic
benefit
greater
reduct
viral
replic
need
achiev
efficaci
reduct
viral
shed
observ
present
trial
similar
howev
report
clinic
trial
tremacamra
solubl
somewhat
greater
produc
pleconaril
medic
produc
small
signific
clinic
benefit
previou
studi
topic
medic
addit
challeng
deliv
medic
site
infect
infect
hrv
involv
larg
lower
airway
addit
nasopharynx
deliveri
locat
might
necessari
obtain
optim
clinic
benefit
final
possibl
spray
enhanc
either
cellular
neural
inflamm
mechan
link
pathogenesi
cold
symptom
futur
studi
histolog
evalu
nasal
mucos
biopsi
sampl
could
provid
addit
inform
regard
preliminari
trial
lowph
nasal
spray
well
toler
healthi
volunt
caus
signific
reduct
nasal
ph
addit
citrat
phytic
acid
ad
prepar
use
inocul
trial
combin
low
ph
chelat
abil
help
boost
antivir
activ
prepar
vitro
data
shown
preliminari
experi
indic
lowph
prepar
contain
phytic
acid
also
well
toler
volunt
data
shown
technic
standpoint
result
demonstr
possibl
lower
nasal
ph
healthi
human
subject
dose
littl
nasal
spray
encouragingli
effect
ph
nasal
caviti
extend
anterior
portion
inferior
turbin
product
deposit
nasopharynx
indic
broad
pattern
deposit
andor
spread
overal
dilut
nasal
secret
buffer
nasal
tissu
result
chang
ph
unit
deliv
product
confirm
use
spray
produc
ph
hostil
hrv
gener
inactiv
exposur
ph
although
clinic
benefit
demonstr
use
model
lowph
nasal
spray
reduc
viral
shed
transmiss
cold
depend
part
shed
larg
amount
viru
conceiv
lowph
treatment
could
use
inhibit
persontoperson
transmiss
fact
tissu
impregn
organ
acid
deterg
abl
reduc
transmiss
cold
clinic
trial
summari
common
respiratori
virus
suscept
low
ph
demonstr
antivir
effect
low
ph
vitro
vivo
despit
antivir
effect
nasal
formul
test
result
statist
signific
reduct
cold
sever
durat
hypothesi
local
irrit
nose
may
obscur
clinic
benefit
less
irrit
acid
spray
develop
could
repres
new
inexpens
antivir
approach
prevent
treatment
cold
caus
hrv
would
warrant
run
larger
scale
human
studi
